<DOC>
	<DOCNO>NCT02757196</DOCNO>
	<brief_summary>prospective , multicenter , randomize , open-label , Phase II , two arm interventional trial perform 5 department hematology China</brief_summary>
	<brief_title>Treatment ITP With Rituximab / Accutane</brief_title>
	<detailed_description>This prospective , multicenter , randomize , open-label , Phase II , two arm interventional trial perform 5 department hematology China . The investigator explore efficacy safety Rituximab plus short-term methylprednisolone compare standard dose methylprednisolone newly diagnose ITP participant .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Clinically confirm immune thrombocytopenic purpura ( ITP ) newly diagnose 2 . Platelet count le 30×109/L two occasion Platelets 30×109/L combined bleed manifestation 3 . Subject ≥ 18 year ≤80years 4 . Subject sign dated write informed consent . 5 . Fertile patient must use effective contraception treatment observational period 6 . Negative pregnancy test 1 . Have impair renal function indicate serum creatinine level &gt; 2.0 mg/dL 2 . Have inadequate liver function indicate total bilirubin level &gt; 2.0 mg/dL and/or aspartate aminotransaminase alanine aminotransferase level &gt; 3×upper limit normal 3 . Have New York Heart Classification III IV heart disease 4 . Have history severe psychiatric disorder unable comply study followup procedure 5 . Have active hepatitis B hepatitis C infection 6 . Have HIV infection 7 . Have active infection require antibiotic therapy within 7 day prior study entry 8 . Are pregnant lactate woman , plan become pregnant impregnate within 12 month receive study drug 9 . Previous treatment rituximab 10 . Previous splenectomy 11 . Had previous concomitant malignant disease 12 . Not willing participate study . 13 . Expected survival &lt; 2 year 14 . Intolerant murine antibody 15 . Immunosuppressive treatment within last month 16 . Connective tissue disease 17 . Autoimmune hemolytic anemia 18 . Patients currently involve another clinical trial evaluation drug treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>Rituximab</keyword>
	<keyword>methylprednisolone</keyword>
</DOC>